Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Authors not listed
Otsuka Pharmaceutical Development & Commercialization, Inc. · 2000
Abstract
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2000). A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type. <em>Otsuka Pharmaceutical Development & Commercialization, Inc.</em>. https://clinicaltrials.gov/study/NCT01438060
Vancouver
Anonymous. A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type. Otsuka Pharmaceutical Development & Commercialization, Inc.. 2000.
BibTeX
@misc{anon2000AMulti,
title = {A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type},
author = {Anonymous},
journal = {Otsuka Pharmaceutical Development & Commercialization, Inc.},
year = {2000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Solvay Pharmaceuticals 2005
Open access · US-GOV
A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Sanofi 2003
Open access · US-GOV
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 2022
Open access · US-GOV
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Ipsen 2002
Open access · US-GOV
Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70
H. Lundbeck A/S 2003
Open access · US-GOV
A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type
University of Zurich 2011
Open access · US-GOV